Comparison of sublingual buprenorphine and intravenous morphine in pain relief and side effects in patients with primary headache admitted in emergency department

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015030821379N1

Enrollment

140

Registered

2015-07-06

Start date

2015-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache. Migraine, Tension-type headache, Cluster headache syndrome

Interventions

Intervention 1: Intervention group who get sublingual buprenorphine 2mg and intravenous placebo then pain measure in times 0, 20, 40, 60 minutes after get drug With Numeric Rating Scale. Interventi

Treatment - Drugs

Placebo

Intervention group who get sublingual buprenorphine 2mg and intravenous placebo then pain measure in times 0, 20, 40, 60 minutes after get drug With Numeric Rating Scale

Control group who get intravenous morphine 0.1 mg per kg and sublingual placebo, Then pain measure in Times 0, 20, 40 , 60 minutes after get drug with Numeric rating scale

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Exclusion criterias: Patients with convulsion; cardiac disorder; liver disorder; nephrogenic disorder; metabolic disorder; temperature more than 38; patients with unstable vital sign (blood pressure under 90); pregnancy; patients with drug addiction; patients with allergy to opioid; patients who get opioid 6 hours before admit to emergency; age under 18 and age upper 55; patients who would not like arrive to study Inclusion criterias: patients with age 18; 55 Years old

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: Numeric rating scale.	—

Secondary

Measure	Time frame
Nausea And Vomiting. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Blood Pressure. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Breathing depression. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Itch. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Drowsiness. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Dizziness. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.	—

Measure

Time frame

Nausea And Vomiting. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Blood Pressure. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Breathing depression. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Itch. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Drowsiness. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.;Dizziness. Timepoint: In times 0, 20, 40, 60 minutes after get drug. Method of measurement: With questionnaire, had or hadn't.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hasan Barzegari

Ahwaz University of Medical Sciences

h_b1979@yahoo.com+98 61 3554 4621

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026